Cannabis Health Symposium Frankfurt
Ingredientpharm’s medical cannabis team will be participating at the Frankfurt Cannabis Health Symposium 2026, a key German and European event dedicated to advancing medical cannabis science, regulatory progress, and patient‑centric innovation.
This year’s symposium brings together researchers, clinicians, policymakers, and industry leaders to discuss how medical cannabis. This can evolve into safer, more standardized, and more accessible therapeutic drug solutions. The agenda highlights exactly what the field needs: evidence‑based dialogue, regulatory clarity, and technological innovation.
Ingredientpharm’s Contribution: Building the Next Generation of Medical Cannabis Drug Solutions
Product manager, Dr. Bastian Arlt, will have two topics in the pocket that are central to the future of medical cannabis:
1. Development of safe and consumer‑friendly medical cannabis drug solutions: Medical cannabis must continue its transition from raw plant material and basic extracts toward pharmaceutical‑grade, predictable, and safe dosage forms. He will discuss how modern formulation science can reduce variability, improve patient adherence, and support regulatory acceptance — ultimately making cannabinoid therapies more reliable for both patients and healthcare providers.
2. Introduction of new extended‑release formulations Extended‑release technologies are a major step forward for cannabinoid therapeutics. They allow for controlled plasma levels, reduced dosing frequency, improved social tolerability, and more consistent therapeutic outcomes. Bastian will present new approaches for creating extended‑release granules, pellets, and oil‑based systems. All formulations align with GMP standards and modern drug‑delivery expectations.
Cannabis Health Symposium: Why New Approaches Matter in Medical Cannabis
The medical cannabis sector is entering a new phase: one defined not by novelty, but by quality, safety, and pharmaceutical rigor. Regulatory agencies across Europe continue to refine their frameworks. Thus, industry must respond with science‑driven innovation and patient‑focused solutions.
We are looking forward to contributing to this important conversation in Frankfurt. Connecting with experts who share the vision of transforming cannabinoids into trusted, modern therapeutics is a key element.
If you will be attending, feel free to reach out.
Expert’s opinion
Medical cannabis is entering a pharmaceutical maturity phase. Advancing safe, consumer‑friendly dosage forms and introducing extended‑release technologies will be essential to ensure consistent plasma levels, improved adherence, and regulatory acceptance. These innovations strengthen therapeutic reliability and support the transition from variable plant‑based products to standardized, evidence‑driven cannabinoid medicines.
